skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Modeling the economic impact of medication adherence in type 2 diabetes: a theoretical approach

Original Research

(1959) Views  (992) Full article downloads

Authors: David S Cobden, Louis W Niessen, Frans FH Rutten, et al

Published Date August 2010 Volume 2010:4 Pages 283 - 290
DOI: http://dx.doi.org/10.2147/PPA.S12121

David S Cobden1, Louis W Niessen2, Frans FH Rutten1, W Ken Redekop1

1Department of Health Policy and Management, Section of Health Economics – Medical Technology Assessment (HE-MTA), Erasmus MC, Erasmus University Rotterdam, The Netherlands; 2Department of International Health, Johns Hopkins University School of Public Health, Johns Hopkins Medical Institutions, Baltimore, MD, USA

Aims: While strong correlations exist between medication adherence and health economic outcomes in type 2 diabetes, current economic analyses do not adequately consider them. We propose a new approach to incorporate adherence in cost-effectiveness analysis.

Methods: We describe a theoretical approach to incorporating the effect of adherence when estimating the long-term costs and effectiveness of an antidiabetic medication. This approach was applied in a Markov model which includes common diabetic health states. We compared two treatments using hypothetical patient cohorts: injectable insulin (IDM) and oral (OAD) medications. Two analyses were performed, one which ignored adherence (analysis 1) and one which incorporated it (analysis 2). Results from the two analyses were then compared to explore the extent to which adherence may impact incremental cost-effectiveness ratios.

Results: In both analyses, IDM was more costly and more effective than OAD. When adherence was ignored, IDM generated an incremental cost-effectiveness of $12,097 per quality-adjusted life-year (QALY) gained versus OAD. Incorporation of adherence resulted in a slightly higher ratio ($16,241/QALY). This increase was primarily due to better adherence with OAD than with IDM, and the higher direct medical costs for IDM.

Conclusions: Incorporating medication adherence into economic analyses can meaningfully influence the estimated cost-effectiveness of type 2 diabetes treatments, and should therefore be ­considered in health care decision-making. Future work on the impact of adherence on health ­economic outcomes, and validation of different approaches to modeling adherence, is warranted.

Keywords: economics, modeling, adherence, diabetes, cost-effectiveness








Readers of this article also read:

Exploring patients’ perceptions for insulin therapy in type 2 diabetes: a Brazilian and Canadian qualitative study
The utility of an electronic adherence assessment device in type 2 diabetes mellitus: a pilot study of single medication
Obesity and the development of type 2 diabetes: the effects of fatty tissue inflammation
Baseline characteristics and initial treatment decisions for patients with schizophrenia at risk of treatment nonadherence
Using systematically observed clinical encounters (SOCEs) to assess medical students’ skills in clinical settings
Introducing students to patient safety through an online interprofessional course
Reduced exercise capacity in persons with Down syndrome: cause, effect, and management
Primary care for diabetes mellitus: perspective from older patients
Impact of pharmacist interventions on patients' adherence to antidepressants and patient-reported outcomes: a systematic review
The impact of HIV clinical pharmacists on HIV treatment outcomes: a systematic review